^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    AFAP1-AS1 (AFAP1 Antisense RNA 1)

    i
    Other names: AFAP1-AS1, AFAP1 Antisense RNA 1, AFAP1 Antisense RNA 1 (Non-Protein Coding), AFAP1 Antisense RNA (Non-Protein Coding)
    8d
    ATMLP Enhances Radioresistance in Non-Small Cell Lung Cancer through AKT-Mediated Lipid Droplet Accumulation. (PubMed, Int J Biol Sci)
    Inhibition of the AKT pathway abrogates ATMLP-induced lipid accumulation and reverses the radioresistant phenotype. These findings identify ATMLP as a key mediator linking ROS homeostasis and lipid metabolic reprogramming to radiation response, and suggest that targeting the ATMLP-AKT axis may represent a promising therapeutic strategy to enhance radiotherapy efficacy in NSCLC.
    Journal
    |
    AFAP1-AS1 (AFAP1 Antisense RNA 1)
    11d
    Detecting Occult Sentinel Node Metastases in HNSCC: The Emerging Role of lncRNAs as Biomarkers and Future Perspectives for USgFNAB Molecular Profiling. (PubMed, Cancers (Basel))
    Future research should prioritize paired tumor-node lncRNA profiling, validation of FNAB-based molecular assays, and integration of multi-omics data for predictive modeling. Overall, integrating lncRNA analysis into ultrasound-guided fine-needle aspiration biopsy may enhance the detection of occult nodal metastases in head and neck squamous cell carcinoma and support more accurate nodal staging in clinically node-negative patients.
    Review • Journal
    |
    MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • HOTAIR (HOX Transcript Antisense RNA) • AFAP1-AS1 (AFAP1 Antisense RNA 1) • MEG3 (Maternally Expressed 3)
    19d
    METTL3 promotes pancreatic cancer immune escape by m6A modification of lncRNA AFAP1-AS1 to enhance EGR2 stability. (PubMed, Eur J Med Res)
    METTL3 enhances AFAP1-AS1 stability via m6A modification recognized by YTHDF2 and IGF2BP1, which subsequently increases EGR2 expression by improving its mRNA stability. EGR2 directly activates transcription of immune checkpoint and epithelial-mesenchymal transition (EMT)-related genes. This METTL3/AFAP1-AS1/EGR2 signaling axis drives PC malignancy and immune resistance, offering potential therapeutic targets for PC treatment.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • AFAP1-AS1 (AFAP1 Antisense RNA 1) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • EGR2 (Early Growth Response 2) • METTL3 (Methyltransferase Like 3) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
    22d
    Retraction: Corrigendum: AFAP1-AS1 promotes epithelial-mesenchymal transition and tumorigenesis through Wnt/β-Catenin signaling pathway in triple-negative breast cancer. (PubMed, Front Pharmacol)
    [This retracts the article DOI: 10.3389/fphar.2020.01107.].
    Journal
    |
    AFAP1-AS1 (AFAP1 Antisense RNA 1)
    22d
    Retraction: AFAP1-AS1 promotes epithelial-mesenchymal transition and tumorigenesis through Wnt/β-catenin signaling pathway in triple-negative breast cancer. (PubMed, Front Pharmacol)
    [This retracts the article DOI: 10.3389/fphar.2018.01248.].
    Journal
    |
    AFAP1-AS1 (AFAP1 Antisense RNA 1)
    3ms
    Long non-coding RNA AFAP1-AS1 promotes alternative splicing of AXIN2 by facilitating SRSFs phase separation to induce drug resistance in lung adenocarcinoma. (PubMed, Mol Cancer)
    Our work uncovers a novel function of AFAP1-AS1 in regulating RNA alternative splicing through the modulation of splicing factors phase separation. This mechanism highlights an unrecognized pathway by which AFAP1-AS1 promotes drug resistance in lung adenocarcinoma, suggesting that AFAP1-AS1 and its regulated splicing events may serve as potential biomarkers or therapeutic targets for the treatment of lung adenocarcinoma.
    Journal
    |
    AFAP1-AS1 (AFAP1 Antisense RNA 1) • AXIN2 (Axin 2) • SRSF3 (Serine And Arginine Rich Splicing Factor 3)
    6ms
    Unveiling the role of RAI14 in cancer: Biological significance and translational perspectives. (PubMed, Semin Oncol)
    Targeting RAI14 as a cancer antigen can also potentially help halt tumor progression. Future large-scale trials are needed to confirm the tumor-regulatory role of RAI14 in human cancer and to evaluate the sensitivity, reliability, and accuracy of using this target as a biomarker or therapeutic target.
    Review • Journal
    |
    mTOR (Mechanistic target of rapamycin kinase) • AFAP1-AS1 (AFAP1 Antisense RNA 1) • RAI1 (Retinoic Acid Induced 1) • MIR23b (MicroRNA 23b)
    6ms
    Investigation of the anticancer effects of doxorubicin-loaded niosomes on HCT-116 cells and the expression levels of LncRNAs DLGAP1-AS1 and AFAP1-AS1 in colorectal cancer. (PubMed, Mol Biol Rep)
    NIOs-DOX demonstrated significant potential to enhance the therapeutic effects of DOX. Additionally, DLGAP1-AS1 and AFAP1-AS1 expression showed limited potential as diagnostic biomarkers in CRC.
    Journal
    |
    AFAP1-AS1 (AFAP1 Antisense RNA 1) • DLGAP1-AS1 (DLGAP1 Antisense RNA 1)
    |
    doxorubicin hydrochloride
    7ms
    Diagnostic value of lnc-RNAs TINCR, GC1 and AFAP1-AS1 in gastric cancer differentiation from healthy people. (PubMed, Biomark Med)
    Our study disclosed the diagnostic utility of plasma HOTIP, BANCR, ZFAS1, TINCR, GC1, and AFAP1-AS1 lncRNAs as appropriate diagnostic biomarkers for gastric cancer. The identification of dysregulated lncRNAs offers promising avenues for noninvasive diagnostic assessment in gastric cancer.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • AFAP1-AS1 (AFAP1 Antisense RNA 1) • TINCR (TINCR Ubiquitin Domain Containing) • CA 19-9 (Cancer antigen 19-9) • ZFAS1 (ZNFX1 Antisense RNA 1)
    7ms
    LncRNA AFAP1-AS1 promoting residual tumor progression after insufficient radiofrequency ablation by up-regulating macropinocytosis in hepatocellular carcinoma. (PubMed, Cell Signal)
    Our findings revealed AFAP1-AS1's oncogenic role and proposed its potential as a diagnostic marker and therapeutic candidate for residual tumor progression and macropinocytosis suppression in HCC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • AFAP1-AS1 (AFAP1 Antisense RNA 1) • MIR139 (MicroRNA 139)
    |
    EGFR expression
    8ms
    Regulation of Human Lung Adenocarcinoma Cell Proliferation by LncRNA AFAP-AS1 Through the miR-508/ZWINT Axis. (PubMed, Int J Mol Sci)
    AFAP1-AS1 accelerates the development of lung adenocarcinoma by cell proliferation, apoptosis, and invasion via the miR-508-3p/ZWINT axis. Thus, targeting AFAP1-AS1 or its downstream regulatory axis could offer novel therapeutic approaches in lung adenocarcinoma treatment.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • AFAP1-AS1 (AFAP1 Antisense RNA 1) • MIR508 (MicroRNA 508) • ZWINT (ZW10 Interacting Kinetochore Protein)
    8ms
    Expression of Concern. (PubMed, Eur Rev Med Pharmacol Sci)
    Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway...PMID: 33577026. The Publisher apologizes for any inconvenience this may cause.
    Journal
    |
    IGF2 (Insulin-like growth factor 2) • MIR200B (MicroRNA 200b) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • FUS (FUS RNA Binding Protein) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • AFAP1-AS1 (AFAP1 Antisense RNA 1) • FOXO3 (Forkhead box O3) • PCNA (Proliferating cell nuclear antigen) • GAS5 (Growth Arrest Specific 5) • SMAD7 (SMAD Family Member 7) • DSCAM (DS Cell Adhesion Molecule) • HOXA-AS2 (HOXA Cluster Antisense RNA 2) • MIR29A (MicroRNA 29a) • MIR483 (MicroRNA 483) • MMP7 (Matrix metallopeptidase 7) • RBM24 (RNA Binding Motif Protein 24) • SNHG7 (Small Nucleolar RNA Host Gene 7) • TGFBR1 (Transforming Growth Factor Beta Receptor 1) • TGIF2 (TGFB Induced Factor Homeobox 2) • WTAP (WT1 Associated Protein) • XIST (X Inactive Specific Transcript) • MAGI2-AS3 (MAGI2 Antisense RNA 3)
    |
    cisplatin